During the past decade, Mater Hospital - North Sydney conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 7 clinical trials were completed, i.e. on average, 87.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mater Hospital - North Sydney" #1 sponsor was "ETOP IBCSG Partners Foundation" with 2 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Breast Cancer Trials, Australia and New Zealand" with 1 trials sponsored and "Jules Bordet Institute" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mater Hospital - North Sydney" #1 collaborator was "Breast International Group" with 2 trials as a collaborator, "ETOP IBCSG Partners Foundation" with 2 trials as a collaborator, "NSABP Foundation Inc" with 2 trials as a collaborator, "Cancer and Leukemia Group B" with 1 trials as a collaborator and "Eastern Cooperative Oncology Group" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Mater Hospital - North Sydney" are "Breast Cancer" (5 trials), "Triple Negative Breast Cancer" (2 trials), "ER-Negative Breast Cancer" (1 trials), "Early Stage Breast Carcinoma" (1 trials) and "HER2 Positive Breast Cancer" (1 trials). Many other conditions were trialed in "Mater Hospital - North Sydney" in a lesser frequency.

Most popular intervention types in "Mater Hospital - North Sydney" are "Drug" (9 trials), "Radiation" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (2 trials), "Carboplatin" (2 trials), "Gemcitabine" (2 trials), "Paclitaxel" (2 trials) and "Sacituzumab Govitecan-hziy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Mater Hospital - North Sydney" are 6 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Mater Hospital - North Sydney". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Mater Hospital - North Sydney, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mater Hospital - North Sydney, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".